Bristol-Myers Squibb shares are trading lower. Barclays maintained an Underweight rating on the stock.
Portfolio Pulse from Benzinga Newsdesk
Bristol-Myers Squibb shares are experiencing a decline after Barclays reiterated its Underweight rating on the stock.
August 22, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol-Myers Squibb shares are trading lower following Barclays' decision to maintain an Underweight rating on the stock.
The Underweight rating from Barclays suggests a negative outlook on Bristol-Myers Squibb, likely contributing to the decline in its stock price. Such ratings can influence investor sentiment and lead to short-term price decreases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100